Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to the Approval for Investigational New Drug by a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

10 June 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

Stock code: 600196	Stock abbreviation: Fosun Pharma	Announcement No.: Lin 2021-085
Bond code: 143020	Bond abbreviation: 17 Fosun 01
Bond code: 143422	Bond abbreviation: 18 Fosun 02
Bond code: 155067	Bond abbreviation: 18 Fosun 03
Bond code: 155068	Bond abbreviation: 18 Fosun 01
Bond code: 175708	Bond abbreviation: 21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval for

Investigational New Drug by a Subsidiary

The board of directors of the Company and all members of the Board warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun

Pharmaceutical Industrial"), a controlling subsidiary of Shanghai Fosun Pharmaceutical

(Group) Co., Ltd.* (the "Company") has recently received the approval for

Investigational New Drug from the National Medical Products Administration of consent to commence clinical trial of Balixafortide (the "Investigational New Drug") licensed to the Group (i.e. the Company and its controlling subsidiaries/entities) for use in combination with Eribulin in the treatment of HER2 negative, locally recurrent or metastatic breast cancer. Fosun Pharmaceutical Industrial intends to conduct clinical trials of the Investigational New Drug in the PRC (excluding Hong Kong and Macau SAR and Taiwan Region, hereinafter the same) in due course as and when the conditions permitted.

1

II. Research Progress of the Investigational New Drug

In August 2020, Fosun Pharmaceutical AG, a controlling subsidiary of the Company ("Fosun Pharma AG") obtained an exclusive license from Polyphor Ltd ("Polyphor") for the clinical development and commercialization of CXCR4 antagonist Balixafortide and its related products/combinations in Mainland China, Hong Kong SAR, Macau SAR and Taiwan region. Fosun Pharma AG is entitled to sub-license its granted rights to its related parties and other third parties as agreed in writing by Polyphor.

As at the date of this announcement, Balixafortide in combination with Eribulin for HER2-negative metastatic breast cancer has completed a Phase Ib clinical study in the United States and is in the process of initiating an international multicenter Phase III clinical study for this indication. Balixafortide in combination with Eribulin for the treatment of HER2-negative metastatic breast cancer has been granted Fast Track qualification by the United States Food and Drug Administration (FDA).

As at the date of this announcement, there is no CXCR4 antagonist has been approved for launch in the PRC for use in breast cancer indications.

As at May 2021, the Group has cumulatively invested in the R&D of the Investigational New Drug in an aggregate amount of approximately RMB96.46 million at the mid-rate of the exchange rate announced by the People's Bank of China as at 31 May 2021. (unaudited; including license fees).

III. Risk Warning

As required by the relevant laws and regulations in the PRC, the Investigational New Drug is subject to undergo clinical studies in the PRC and approval from the competent national drug review department before it comes onto the market. There are certain risks in the clinical trial based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and marketing of the new drug is a long-term task involving various uncertainties. Investors should be aware of the investment risks.

2

Announcement is hereby given.

The Board of Directors of

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

10 June 2021

3